The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ANAPTYSBIO INC COM 032724106 56,648 2,628,678 SH   OTR 1 0 2,628,678 0
APTEVO THERAPEUTICS INC COM NEW 03835L207 53,715 1,760,000 SH   OTR 1 0 1,760,000 0
BCTG ACQUISITION CORP COM 05492W103 5,213 468,750 SH   OTR 1 0 468,750 0
COHERUS BIOSCIENCES INC COM 19249H103 9,497 650,000 SH   OTR 1 0 650,000 0
EQUILLIUM INC COM 29446K106 4,290 600,000 SH   OTR 1 0 600,000 0
LA JOLLA PHARMACEUTICAL CO COM 503459604 39,879 9,405,490 SH   OTR 1 0 9,405,490 0
ODONATE THERAPEUTICS INC COM 676079106 53,060 15,514,566 SH   OTR 1 0 15,514,566 0
RELMADA THERAPEUTICS INC COM 75955J402 7,042 200,000 SH   OTR 1 0 200,000 0
ROCKET PHARMACEUTICALS INC COM 77313F106 112,336 2,531,800 SH   OTR 1 0 2,531,800 0
VINCERX PHARMA INC COM NEW 92731L106 9,650 500,000 SH   OTR 1 0 500,000 0
VINCERX PHARMA INC *W EXP 12/24/202 92731L114 4,098 1,014,368 SH   OTR 1 0 1,014,368 0